NASDAQ:MSLE Satellos Bioscience (MSLE) Stock Price, News & Analysis $5.85 +0.10 (+1.74%) Closing price 06/17/2026 04:00 PM EasternExtended Trading$5.84 -0.01 (-0.17%) As of 06/17/2026 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Satellos Bioscience Stock (NASDAQ:MSLE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Satellos Bioscience alerts:Sign Up Key Stats Today's Range$5.72▼$5.8550-Day Range$5.59▼$8.7052-Week Range$4.54▼$13.39Volume19,417 shsAverage Volume31,750 shsMarket Capitalization$121.86 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingModerate Buy Company Overview Satellos Bioscience Inc. is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario. Read More Satellos Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreMSLE MarketRank™: Satellos Bioscience scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingSatellos Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSatellos Bioscience has a consensus price target of $18.00, representing about 207.7% upside from its current price of $5.85.Amount of Analyst CoverageSatellos Bioscience has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Satellos Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Satellos Bioscience are expected to decrease in the coming year, from ($1.69) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Satellos Bioscience is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSatellos Bioscience has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.59% of the float of Satellos Bioscience has been sold short.Short Interest Ratio / Days to CoverSatellos Bioscience has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Satellos Bioscience has recently decreased by 9.47%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSatellos Bioscience does not currently pay a dividend.Dividend GrowthSatellos Bioscience does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.45 News SentimentSatellos Bioscience has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Satellos Bioscience this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Satellos Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Satellos Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders37.90% of the stock of Satellos Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsSatellos Bioscience has minimal institutional ownership at this time.Read more about Satellos Bioscience's insider trading history. Receive MSLE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Satellos Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MSLE Stock News HeadlinesSatellos Bioscience Announces Results of Annual Meeting of ShareholdersJune 17 at 5:10 PM | financialpost.comFSatellos Bioscience Announces Results of Annual Meeting of ShareholdersJune 17 at 5:08 PM | markets.businessinsider.comSpaceX will crumble without these 5 companiesThe SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate. Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook. | InvestPub (Ad)Satellos Bioscience Posts 2025 Results, Advances SAT-3247 Into Global Phase 2 Duchenne TrialsJune 15 at 5:11 PM | theglobeandmail.comSatellos Bioscience (MSLE) Receives a Buy from GuggenheimMay 21, 2026 | theglobeandmail.comSatellos Bioscience Inc MSLEMay 21, 2026 | morningstar.comMSatellos Bioscience Inc.: Satellos Reports First Quarter 2026 Financial Results and Highlights Company ProgressMay 15, 2026 | finanznachrichten.deSatellos Bioscience to Showcase DMD Program at April Bloom Burton Healthcare Investor ConferenceApril 9, 2026 | tipranks.comSee More Headlines MSLE Stock Analysis - Frequently Asked Questions How have MSLE shares performed this year? Satellos Bioscience's stock was trading at $11.27 at the start of the year. Since then, MSLE shares have decreased by 48.1% and is now trading at $5.85. How were Satellos Bioscience's earnings last quarter? Satellos Bioscience Inc. (NASDAQ:MSLE) released its quarterly earnings results on Friday, May, 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.02. How do I buy shares of Satellos Bioscience? Shares of MSLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2026Today6/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:MSLE CIK1421642 WebN/A Phone(905) 336-6128Fax604-602-9699EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Satellos Bioscience$18.00 High Price Target$23.00 Low Price Target$11.00 Potential Upside/Downside+207.7%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.87 million Net MarginsN/A Pretax MarginN/A Return on Equity-63.10% Return on Assets-58.03% Debt Debt-to-Equity RatioN/A Current Ratio16.48 Quick Ratio16.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book3.25Miscellaneous Outstanding Shares20,830,000Free Float12,936,000Market Cap$121.86 million OptionableN/A Beta1.54 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:MSLE) was last updated on 6/18/2026 by MarketBeat.com Staff. From Our PartnersBuy now or wait?SpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much...Altimetry | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Satellos Bioscience Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Satellos Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
